Images List Premium Download Classic

Diabetes

Diabetes-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Methods of obtaining islet cells
Lothian Health Board
June 22, 2017 - N°20170175081

The present invention provides methods and materials relating to obtaining or expanding populations of islet cells, and uses of the islet cells obtained by these methods, for example in the treatment of diabetes. The invention uses transcription factors in a process of expansion and de-differention, followed by redifferentiation.
Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof
Infinitus (china) Company Ltd
June 22, 2017 - N°20170173103

Compositions and preparation method thereof, said compositions comprise herb extract from a mixture comprising cyclocarya paliurus leaf and one or two herbs selected from the group consisting of puerariae lobatae radix and polygonati odorati rhizoma, said compositions can treat diabetes, hyperglycemia, hypertension and/or hyperlipidemia.
Tea composition comprising cyclocarya paliurus and preparation method and uses thereof
Infinitus (china) Company Ltd
June 22, 2017 - N°20170173101

Compositions and preparation method thereof, said compositions comprise cyclocarya paliurus leaf and one or more herbs selected from the group consisting of green tea, mori folium, siraitiae fructus, broadleaf holly leaf and polygonati odorati rhizoma, and their preparation method. Said compositions can treat diabetes, hyperglycemia, hypertension and/or hyperlipidemia.
Diabetes Patent Pack
Download 521+ patent application PDFs
Diabetes Patent Applications
Download 521+ Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • 521+ full patent PDF documents of Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Apoptosis signal-regulating kinase inhibitors
Infinitus (china) Company Ltd
June 22, 2017 - N°20170173031

Wherein variables are as defined above. The compounds have apoptosis signal-regulating kinase (“ask1”) inhibitory activity, and are thus useful in the treatment of ask1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, copd, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver ...
Antidiabetic medications
Boehringer Ingelheim International Gmbh
June 22, 2017 - N°20170173027

Methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia, among others.
Methods and devices for the diagnosis and treatment of diabetes
Theranova, Llc
June 22, 2017 - N°20170172469

Methods and devices for the diagnosis and treatment of diabetes are disclosed in which an analyte concentration within a peritoneal fluid of a human subject may be determined by implanting an analyte sensor apparatus in the subject where the apparatus may comprise a housing and a flexible sensing catheter which has a lumen with a plurality of apertures and an ...
Diabetes Patent Pack
Download 521+ patent application PDFs
Diabetes Patent Applications
Download 521+ Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • 521+ full patent PDF documents of Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Esculentin-2cha peptide and analogues thereof
University Of Ulster
June 15, 2017 - N°20170166614

The present invention relates to an esculentin-2cha peptide and analogues thereof, and the use each thereof in the treatment of diabetes, for example type 2 diabetes; insulin resistance; obesity, and/or hypercholesterolemia. Also disclosed is a pharmaceutical composition comprising peptides and analogues according to the present invention; use of peptides and analogues according to the present invention for the manufacture ...
Antidiabetic substituted heteroaryl compounds
Merck Sharp & Dohme Corp.
June 15, 2017 - N°20170166578

The present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula i are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes ...
O-glcnac transferase (ogt) inhibitors and uses thereof
The United States Of America, As Represented By The Secretary, Department Of Health And Human
June 15, 2017 - N°20170166558

The present invention provides inhibitors of o-glcnac transferase. Typically, the inhibitors are quinolinone-6-sulfonamides. The invention also provides pharmaceutical compositions thereof and methods for using the same in diabetes and complications thereof, metabolic diseases, neurodegenerative diseases, proliferative diseases (e. G., cancers), autoimmune diseases, and inflammatory diseases.
Process for the preparation of dapagliflozin
Cadila Healthcare Limited
June 15, 2017 - N°20170166547

Dapagliflozin compounds and process for dapagliflozin preparation are described. Pharmaceutical compositions comprising dapagliflozin or solvates of dapagliflozin, for the treatment of diabetes are also described.
Compositions and methods for treating diabetes and liver diseases
Cempra Pharmaceuticals, Inc.
June 15, 2017 - N°20170165286

Compounds, compositions, and methods are described herein for treating diabetes, fatty liver diseases, fibrotic diseases, such as liver and pulmonary fibrosis, and hepatocellular carcinoma.
Heteroaromatic compounds and their use as dopamine d1 ligands
Cempra Pharmaceuticals, Inc.
June 15, 2017 - N°20170165270

And pharmaceutically acceptable salts thereof and n-oxides thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) and the uses of such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) for the treatment of ...
Mutation for type i diabetes mellitus and animal model
Medizinische Hochschule Hannover
June 15, 2017 - N°20170164589

The invention relates to a mutation in the dock8 encoding gene that is causative for type 1 diabetes mellitus at least in the rat (rattus norvegicus) or mouse, the rat or mouse preferably having an mhc predisposing towards type 1 diabetes mellitus and/or a mutation in the von willebrand factor vwa2. Embodiments of the invention comprise a process for generating a ...
Diabetes Patent Pack
Download 521+ patent application PDFs
Diabetes Patent Applications
Download 521+ Diabetes-related PDFs
For professional research & prior art discovery
inventor
  • 521+ full patent PDF documents of Diabetes-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
High load enzyme immobilization by crosslinking
Roche Diabetes Care, Inc.
June 08, 2017 - N°20170159039

Methods of cross-linking polypeptide molecules are provided, where such methods include combining a cross-linking agent and polypeptide molecules in a solution under conditions suitable for a cross-linking reaction to occur. Also provided are preparations of cross-linked polypeptide molecules, where the polypeptide molecules are cross-linked by essentially unbranched cross-linking groups of at least 40 contiguous atoms. Further provided are test chemistry matrices ...
Novel compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and ...
Katholieke Universiteit Leuven K.u. Leuven R & D
June 08, 2017 - N°20170158684

The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral ...
Co-crystal of dapagliflozin with citric acid
Sun Pharmaceutical Industries Limited
June 08, 2017 - N°20170158659

The present invention relates to a dapagliflozin-citric acid co-crystal, processes for its preparation, and its use for the treatment of type 2 diabetes mellitus. A dapagliflozin citric acid co-crystal. The dapagliflozin citric acid co-crystal of claim 1, characterized by x-ray powder diffraction peaks having d-spacing values at about 3. 89, 3. 90, 4. 01, 4. 35, 5. 77, and 5. 80.
Method for producing 4,4,7-trifluoro-1,2,3,4-tatrahydro-5h-1-benzazepine compound and intermediate used in the method
Tacurion
June 08, 2017 - N°20170158639

The present invention provides a method for producing a 4,4,7-trifluoro-1,2,3,4-tetrahydro-5h-1-benzazepine compound which has an superior agonistic activity to an arginine vasopressin v2 receptor and is useful as an active ingredient for a pharmaceutical composition for preventing and/or treating urinary frequency, urinary incontinence, enuresis, central diabetes insipidus, nocturia, nocturnal enuresis, or the like; and useful intermediates for ...
Methods for inducing insulin production and uses thereof
Universite De Geneve
June 08, 2017 - N°20170157110

The invention relates to methods of inducing insulin production in delta-cells and/or converting delta-cells into insulin producing cells, as well as methods of preventing and/or treating diabetes and agents and compositions useful in said methods.
Early prediction markers of diabetic nephropathy
Chu Montpellier
June 01, 2017 - N°20170153249

The present invention concerns a method for the in vitro detection of an increased risk of diabetic nephropathy in a subject suffering from diabetes and being normoalbuminuric. Another aspect of the invention pertains to a method for the in vitro identification of a marker for prediction of diabetic nephropathy. Finally, the invention concerns a kit comprising means for detecting at ...
Inhibitors of the farnesoid x receptor and uses in medicine
The Penn State Research Foundation
June 01, 2017 - N°20170152283

Disclosed are inhibitors of the farnesoid x receptor, for example of formula (i), wherein r1, r2, r4, x, y, z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier ...
Crystalline solvate forms of a pharmaceutical
Neurmedix, Inc.
June 01, 2017 - N°20170152281

The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include form i anhydrate and form iv and form v solvates. The invention further relates to solid ...
Loading